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Abstract The presence of distant metastases at initial
evaluation influences treatment selection, since no effec-
tive systemic treatment for disseminated head and neck
squamous cell carcinoma (HNSCC) is currently available.
The reported sensitivity for the detection of distant
metastases by contrast-enhanced (ce)CT and FDG-PET(/
CT) differs substantially between studies. We hypothesized
that these sensitivity values are highly dependent on the
reference standard use, e.g., follow-up term. Therefore, we
analyze our results of FDG-PET/CT (including chest ceCT)
with long-term follow-up and compare these findings with
data from the literature, with particular interest in the dif-
ferent reference standards. Forty-six HNSCC patients with
high-risk factors underwent pretreatment screening for
distant metastases by FDG-PET/CT (including chest
ceCT). In 16 (35%) patients, distant metastases were
detected during screening (6 patients) or during a mean
follow-up of 39.4 months after screening (10 patients). The
sensitivity and negative predictive value were 83.3 and
97.2% when 6 months, 60.0 and 89.9% when 12 months,
and 37.5 and 72.2% when 30 months follow-up were used
as reference standard, respectively. This is comparable
with reported studies with similar reference standards. This
critical appraisal on the reference standards used in our and
reported studies shows room for improvement for the
detection of distant metastases to refrain more patients
from unnecessary extensive locoregional treatment for
occult metastatic HNSCC.
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Introduction
Head and neck squamous cell carcinoma (HNSCC)
accounts for approximately 5% of all malignant tumors
worldwide. Two-thirds of the patients with HNSCC present
with advanced disease. HNSCC preferentially metastasize
to regional lymph nodes rather than spread hematoge-
nously. Distant metastases usually occur late in the course
of the disease. As results of locoregional treatment have
improved significantly over the last decades, more patients
are at risk to develop second primary tumors and distant
metastases [1].
The presence of distant metastases at initial evaluation
influences the prognosis and thus treatment selection: since
no effective systemic treatment for disseminated HNSCC
is currently available, patients with distant metastases are
generally not considered curable and often receive only
palliative treatment [2]. Therefore, screening for distant
metastases is important to avoid futile treatments with
extensive burden to patients and high costs.
The reported prevalence of clinically identified distant
metastases in HNSCC at presentation is generally consid-
ered too low to warrant routine screening for distant
metastases in all HNSCC patients. The risk of hematoge-
neous spread is directly related to the stage of disease,
particularly to the presence and extent of lymph node
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metastases, and locoregional control. The yield of screen-
ing for distant metastases depends on the applied diag-
nostic methods [3]. High-risk factors have been identified
and validated: C3 lymph node metastases, bilateral lymph
node metastases, lymph node metastases C6 cm, low
jugular lymph node metastases, regional recurrence, and
second primary tumors [4–7]. Using these selection crite-
ria, distant metastases were detected in 29–45% of the
patients during initial screening using chest CT and/or
FDG-PET (18–19%) or within 12-month follow-up
(11–14%) [4–7]. Unfortunately, 20% of these high-risk
patients who had a negative contrast enhanced CT (ceCT)
of the chest at presentation developed distant metastases
within 12 months after therapy with curative intent. In one-
third of the cases, these missed distant metastases were
extrathoracic.
We and others [8] have shown that adding FDG-PET to
contrast-enhanced chest CT improves the accuracy and
yield of staging, yielding a sensitivity of 63% with a
horizon of 12-month follow-up in a prospective multi-
center study [6]. However, still 15% of these high-risk
patients who had a negative chest CT and whole body
FDG-PET at presentation developed distant metastases
within 12 months after therapy with curative intent [8].
Since in almost half of the patients the presence of distant
metastases was missed, room for improvement remains.
New developments like the integrated combination of
PET and CT (PET/CT) may improve the detection of
(occult) distant metastases. A meta-analysis on integrated
FDG-PET/CT showed for the detection of distant metas-
tases and second primary cancers in head and neck cancer
patients a pooled sensitivity of 89% and a specificity of
95% [9]. However, there was a striking range of sensitivity
values (Table 1) [5, 6, 8, 12–18]. In previous studies with a
long-term follow-up, we reported a sensitivity of only
55–63% [6, 19].We hypothesized that these sensitivity
values are highly dependent on the reference standard use,
e.g., follow-up term. Therefore, we analyze our results of
FDG-PET/CT (including chest ceCT) with long-term fol-
low-up and compare these findings with data from the lit-
erature, with particular interest in the different reference
standards.
Materials and methods
Patients and study design
We performed a retrospective cohort study on the yield of
screening for distant metastases with whole body FDG-
PET/CT (including chest ceCT) in high-risk head and neck
cancer patients treated at the VU University Medical
Center between April 2007 and August 2009. Patients were
eligible for screening for distant metastases when meeting
the following criteria: (1) HNSCC; (2) candidates for
extensive treatment with curative intent (surgery and/or
radiotherapy with or without chemotherapy); (3) minimum
of 12-month follow-up; in case, no distant metastases were
detected at initial presentation; (4) high-risk factors for
development of distant metastases [7].
HNSCC was histologically confirmed in all cases, and
all other histological subtypes were excluded. Because of
their distinct metastatic patterns, squamous cell carcinoma
of skin, nasopharynx, nasal cavity, and paranasal sinus was
excluded. Finally, patients who rejected further workup,
patients who died during the first year of follow-up due to
other causes than metastatic HNSCC and those who were
lost before 1-year follow-up because of other reasons were
excluded.
Forty-six patients (33 men and 13 women) with a mean
age of 61 years (range 33–76) met aforementioned criteria.
These patients had the following high-risk factors: C3
lymph node metastases (n = 10), bilateral lymph node
metastases (n = 13), lymph node metastases of C6 cm
(n = 5), low jugular lymph node metastases (n = 5),
regional recurrence (n = 7), and second primary tumours
(n = 16), as assessed by palpation, CT, MRI, and/or
ultrasound-guided fine-needle aspiration cytology. Some
patients had more than one high-risk factor. Primary tumor
sites were the oral cavity (n = 14), oropharynx (n = 16),
hypopharynx (n = 8), and larynx (n = 11). Two patients
had an unknown primary tumor. Five patients had syn-
chronous second primary tumors. Patients were primary
treated by surgery (n = 20), radiotherapy (n = 8),
chemoradiation (n = 17), and chemotherapy (n = 1).
As part of the pretreatment workup, all patients under-
went a panendoscopy, ce CT and/or magnetic resonance
imaging (MRI) of the head and neck. If considered indi-
cated, fine-needle aspiration of cervical lymph nodes was
performed. Post-treatment follow-up was performed by
regular visits to the outpatient clinic (every 6–8 weeks in
the first year, with increasing intervals in following years).
The mean follow-up was 39.4 months (range 1.7–90.2;
median 30.2 months). No routine imaging screening for
distant metastases was planned during follow-up, but
additional examination was performed when suspicion
arose either through the patient history or physical exam-
ination (e.g., weight loss, lesions/complaints suspicious of
recurrence). Six patients developed a locoregional recur-
rence during follow-up.
18FDG-PET/CT
All patients underwent FDG-PET/CT pretreatment. During
our study period, both the Gemini TF-64 and Ingenuity TF
integrated PET/CT systems (Philips Medical Systems,
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Best, The Netherlands) were used to perform whole body
(from mid-thighs to skull vertex) FDG-PET/CT scans,
followed in the same scan session with ceCT of the chest.
Patients fasted for at least 6 h prior to scanning, which
started approximately 60 min after intravenous FDG
administration. The dose administered was 2.5-MBq/kg
body weight (±10%). Glucose levels were checked prior to
18FDG administration. Low-dose CT was performed with
120 kV and 50 mAs prior to emission scanning. PET–CT
data were reconstructed using a time of flight row-action
maximum likelihood algorithm, as implemented by the
vendor. Final image matrix size equals 288 9 288 with a
voxel size of 2 9 2 9 2 mm. Post-reconstruction image
resolution was 5-mm full width at half maximum
(FWHM).Preparation and scanning were performed
according to EANM guidelines [10].
The FDG PET/low-dose CT images were interpreted by
experienced nuclear medicine physicians and the ceCT
scans by experienced radiologists, concluded with a joint
reading session to integrate the findings. Readers had
access to all relevant clinical information, according to
common clinical practice. Most lesions suspicious of being
malignant on FDG-PET/CT were confirmed using addi-
tional (follow-up) imaging, endoscopic workup and/or
biopsy, using a rational approach. In a few cases, findings
of FDG PET/CT were considered unequivocal regarding
the presence of distant metastases, and consensus was
reached not to perform additional workup by the multi-
disciplinary team.
Scoring criteria
Radiological criteria for lung metastases were: (multiple)
smoothly defined lesions mostly located subpleurally and
at the end of a blood vessel. FDG uptake was considered
suspicious for malignancy in the case of enhanced uptake
Table 1 Clinical studies on detection of distant metastases in HNSCC patients with follow-up as reference standard
Study Technique Patients N Sensitivity (%) Specificity (%) PPV (%) NPV (%) Follow-up
(months)
Fakhry et al. [17] CECT chest All 37 100 92 86 100 6
Krabbe et al. [16] CECT chest All 82 55 63 21 88 [6
Brouwer et al. [5] CECT chest High risk 109 63 86 71 81 12
Brouwer et al. [5] CECT chest High risk LRC 104 73 86 71 87 12
Senft et al. [6] CECT chest High risk 92 37 (24–52) 95 (88–98) 79 (57–91) 75 (66–82) 12
Senft et al. [6] CECT chest High risk LRC 80 50 (33–67) 95 (88–98) 79 (57–91) 83 (75–90) 12
Ng et al. [8]a CECT chest All 160 50 (30–70) 98 (94–100) 81 (54–96) 91 (85–95) 12
Teknos et al. [13] CECT chest Advanced 12 33 100 100 33 24
Suenaga et al. [18] CT chest Recurrentb 170 33 (10–57) 99 (98–100) 83 (54–100) 94 (90–98) [12
Krabbe et al. [16] PET All 149 85 94 58 98 [6
Senft et al. [6] PET High risk 92 53 (39–67) 93 (86–97) 80 (62–91) 80 (71–86) 12
Senft et al. [6] PET High risk LRC 80 68 (51–82) 93 (86–97) 79 (61–90) 89 (80–94) 12
Ng et al. [8]a PET All 160 77 (56–91) 94.0 (89–97) 71 (51–87) 95.5 (90–98) 12
Teknos et al. [13] PET Advanced 12 100 100 100 100 24
Haerle et al. [12] PET/non-ceCT Advanced 299 97 95 67 100 6
Fahkry et al. [17] PET/non-ceCT All 37 92 85 73 96 6
Gourin et al. [14] PET/non-ceCT All 27 60 95 75 91 12
Gourin et al. [15] PET/non-ceCT Recurrent 64 86 84 60 95
Suenaga et al. [18] PET/non-ceCT Recurrentb 170 53 (28–79) 99 (98–100) 89 (68–100) 96 (93–99) [12
Haerle et al. [12] PET/non-ceCT Advanced 299 48 94 67 88 30@
Senft et al. [6] PET ? ceCT High risk 92 63 (48–76) 95 (88–98) 86 (70–94) 84 (75–90) 12
Senft et al. [6] PET ? ceCT High risk LRC 80 82 (65–92) 95 (88–98) 86 (69–94) 93 (86–97) 12
Ng et al. [8]a PET ? ceCT All 160 81 (61–93) 99 (95–100) 91 (72–100) 96 (91–99) 12
Suenaga et al. [18] PET/ceCT Recurrentb 170 60 (35–85) 99 (98–100) 90 (71–100) 96 (94–99) [12
95% confidence intervals between brackets if available
N number of patients, LRC patients with locoregional recurrence and distant metastases during follow-up excluded
@median follow-up 30 months (range 1–72)
a Distant metastases and second primary tumors
b Suspicious for recurrence
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incompatible with its physiological bio-distribution. In all
patients, every scan report (chest ceCT and whole body
FDG-PET/CT) was retrospectively scored for suspicious-
ness of distant metastases using a five-point ordinal Likert-
scale: 0 = no lesion/uptake, 1 = definitively benign,
2 = probably benign, 3 = equivocal, 4 = probably
malignant and 5 = definitely malignant. If more lesions
were scored in a single patient, the lesion with the highest
score was used for statistical analysis. The Likert scale was
reduced to a binominal sensitive scale (0–2 = negative,
3–5 = positive) and conservative scale (0–3 = negative,
4–5 = positive) to obtain accuracy data for ceCT and
FDG-PET/CT.
Criteria for combined and integrated chest ceCT and
whole body FDG-PET/CT reading were based on a pre-
vious study [6]: positive if PET shows FDG uptake (Likert
[0) or if PET shows no uptake and CT is positive (Likert 4
or 5) in small lesions below the detection limit (5 mm) of
PET; and negative in all other scorings.
Although the primary goal was screening for distant
metastases, we also registered second primary tumors.
Patients with second primary tumors outside the head and
neck region, which were found during screening, were
described separately.
Statistical analysis
FDG PET/CT or chest CT findings suspicious of being
metastases were considered positive. If no suspicious
lesion or lesions suspicious of being either benign or sec-
ond primary tumors were found, the scan was considered
negative. The FDG PET/CT and chest CT findings were
compared to the findings of further initial workup and
findings during follow-up. Negative findings on FDG PET/
CT in patients who developed distant metastases during
follow-up were considered as being false-negative,
assuming these metastases were (subclinically) present at
time of screening.
The result of the clinical diagnostic workup between
screening until a follow-up of 12 months was used as
reference standard, and patients were classified as positive
or negative with respect to the presence of distant metas-
tases. Other reference standards used were follow-up of
6 months and long-term follow-up.
In a separate analysis, these results were corrected for
locoregional recurrence, since no distinction can be made
between growth of subclinical metastases already present
at the time of screening and reseeding of a locoregional
recurrence after initial screening.
Sensitivity, specificity, positive, and negative predictive
values of the chest ceCT, FDG PET/non-ceCT, and FDG
PET/ceCT for detection of distant metastases were calculated.
Results
In 22 of the total group of 46 patients (48%), distant
metastasis (n = 16; 35%) or a second primary tumor
(n = 6; 13%) was detected during screening or during
follow-up after screening. Pretreatment screening identified
distant metastases in six patients (13%) and a second pri-
mary tumor in 1 patient. Distant metastases were located in
the lungs (n = 14), bone (n = 4), liver (n = 2), and skin
(n = 1). In six patients, locoregional recurrence was
observed; three of these patients developed distant metas-
tases during follow-up.
Sensitivity, specificity, positive predictive value, and
negative predictive value of the different imaging modal-
ities, scoring, and reference standard are shown in Table 2.
By sensitive reading and using a reference standard of
6 months, the sensitivity of ceCT, PET/non-ceCT, and
PET/ceCT was 67.7, 66.7, and 83.3%, but these fig-
ures decreased when a follow-up of 30 months was used to
37.5, 25.0, and 37.5%, respectively.
Discussion
For the detection of distant metastases in HNSCC patients,
chest CT and whole body FDG-PET are the most important
diagnostic imaging techniques. However, studies are dif-
ficult to compare, and the real value is difficult to assess
because of methodological differences. Unfortunately,
some studies in head and neck cancer include tumor types
other than HNSCC (e.g., nasopharyngeal carcinoma and
salivary gland tumors) or sites with different clinical
behavior (e.g., nasopharynx, nasal cavity, and paranasal
sinus) and heterogeneous disease stages. The incidence of
distant metastases (depending on type and stage) may
influence predictive values of tests. Even more important is
the reference standard used. Distant metastases that appear
during follow-up in patients who achieved locoregional
control must have arisen from subclinical distant spread
already present at the time of treatment. Thus, if patients
with locoregional disease control develop distant metas-
tases despite negative screening, these distant metastases
were missed (below the detection limit) by the technique
used for screening. The best references are long-term fol-
low-up and autopsy. The longer the follow-up, the higher
the chance that occult distant metastases become manifest
and the sensitivity and negative predictive value are
expected to decrease. Spector et al. [11] performed a ret-
rospective study on 170 patients who developed distant
metastases: only 16.5% of patients had distant metastasis at
presentation, and the remaining patients were diagnosed
with distant metastases at a median of 324 days from
1116 Eur Arch Otorhinolaryngol (2017) 274:1113–1120
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HNSCC diagnosis [11]. In the study of Haerle et al. [12],
the median time before metachronous ([6 months after
screening) distant metastases became manifest was
11 months (range 7–34 months). Thus, only about half of
the missed or metachronous distant metastases will be
diagnosed within 12-month follow-up. In this study, the
median follow-up was 30.2 months. The number of clinical
studies with a clearly defined follow-up as reference stan-
dard is limited (Table 1).
Brouwer et al. [5] reported on 109 HNSCC patients with
risk factors for distant metastases who underwent
pretreatment screening by chest CT. Distant metastases
were detected in 19% of these patients. Despite negative
screening with chest CT, 9 (11%) patients developed dis-
tant metastases within a 12-month follow-up period. Using
a follow-up of 12 months as reference standard and
excluding patients with distant metastases as well as
locoregional recurrence during follow-up, the sensitivity
and specificity of the chest CT for the detection of distant
metastases were 73 and 86%, respectively [5]. This is
comparable with the sensitivity of 60% and specificity of
84.8% found in the present study. Using the same risk
Table 2 Results of scoring chest ceCT, whole body FDG-PET/CT and integrated PET/CT and ceCT using different reference standards (12 and
6 months and median 30.2-month follow-up) and conservative and sensitive reading and reading according to Senft et al. [6]
Scoring Follow-up (months) Sensitivity % Specificity % PPV % NPV %
ceCT chest
Conservative 30 18.8 (4.0–45.6) 96.7 (82.8–99.9) 75.0 (19.4–99.4) 69.0 (52.9–82.4)
12 23.1 (5.0–53.8) 97.0 (84.2–99.9 75.0 (19.4–99.4) 76.2 (60.5–87.9)
6 33.3 (7.5–70.1) 97.3 (85.8–99.9) 75.0 (19.4–99.4) 85.7 (71.5–94.6)
LRC 30 23.1 (5.0–53.8) 96.7 (82.8–99.9) 75.0 (19.4–99.4) 74.4 (57.9–87.0)
12 30.0 (6.7–65.2) 97.0 (84.2–99.9) 75.0 (19.4–99.4) 82.0 (66.5–92.5)
6 67.7 (22.3–95.7) 97.3 (85.8–99.9) 80.0 (28.4–99.5) 94.7 (82.3–99.4)
Sensitive 30 37.5 (15.2–64.6) 83.3 (65.3–94.4) 54.5 (23.4–83.3) 71.4 (53.7–85.4)
12 46.2 (19.2–74.9) 84.8 (68.1–94.9) 54.5 (23.4–83.3) 80.0 (63.1–91.6)
6 67.7 (29.9–92.5) 86.5 (71.2–95.5) 54.5 (23.4–83.3) 91.4 (76.9–98.2)
LRC 30 46.1 (19.2–74.9) 83.3 (65.3–94.4) 54.5 (23.4–83.3) 78.1 (60.0–90.7)
12 60.0 (26.2–87.8) 84.8 (68.1–94.9) 54.4 (23.4–83.3) 87.5 (71.0–96.5)
6 66.7 (22.3–95.7) 81.1 (64.8–92.0) 36.4 (10.9–69.2) 93.8 (79.2–99.2)
PET/non-ceCT
Conservative 30 18.8 (4.0–45.6) 100.0 (88.4–100.0) 100.0 (29.2–100.0) 70.0 (53.9–82.8)
12 30.0 (6.7–65.2) 100.0 (88.4–100.0) 100.0 (29.2–100.0) 83.7 (69.3–93.2)
6 50.0 (11.8–88.2) 100.0 (88.4–100.0) 100.0 (29.2–100.0) 93.0 (80.9–98.5)
LRC 30 23.1 (5.0–53.8) 100.0 (88.4–100.0) 100.0 (29.2–100.0) 75.0 (58.8–87.3)
12 30.0 (6.7–65.2) 100.0 (88.4–100.0) 100.0 (29.2–100.0) 82.5 (67.2–92.7)
6 50.0 (11.8–88.2) 100.0 (88.4–100.0) 100.0 (29.2–100.0) 92.5 (79.6–98.4)
Sensitive 30 25.0 (7.3–52.4) 90.0 (73.5–97.9) 57.1 (18.4–90.1) 69.2 (52.4–83.0)
12 40.0 (12.2–73.8) 91.7 (77.5–98.2) 57.1 (18.4–90.1) 84.6 (69.5–94.1)
6 66.7 (22.3–95.7) 92.5 (79.6–98.4) 57.1 (18.4–90.1) 94.9 (82.7–99.4)
LRC 30 30.8 (9.1–61.4) 90.0 (73.5–97.9) 57.1 (18.4–90.1) 75.0 (57.8–87.9)
12 40.0 (12.2–73.8) 90.9 (75.7–98.1) 57.1 (18.4–90.1) 83.3 (67.2–93.6)
6 66.7 (22.3–95.7) 81.9 (78.1–98.3) 57.1 (18.4–90.1) 94.4 (81.3–99.3)
PET/CT and chest ceCT
According to Senft et al. [6] 30 37.5 (15.2–64.6) 86.7 (69.3–96.2) 60.0 (26.2–87.8) 72.2 (54.8–85.8)
12 60.0 (26.2–87.8) 89.9 (73.9–96.9) 60.0 (26.2–87.8) 89.9 (73.9–96.9)
6 83.3 (35.9–99.6) 87.5 (73.2–95.8) 50.0 (18.7–81.3) 97.2 (85.5–99.9)
LRC 30 46.1 (19.2–74.9) 86.7 (69.3–96.2) 60.0 (26.2–87.8) 78.8 (61.1–91.0)
12 60.0 (26.2–87.8) 87.9 (71.8–96.6) 60.0 (26.2–87.8) 87.9 (71.8–96.6)
6 60.0 (26.2–87.8) 87.9 (71.8–96.6) 60.0 (26.2–87.8) 87.9 (71.8–96.6)
LRC locoregional control (patients with locoregional recurrence and distant metastases during follow-up excluded), PPV positive predictive
value, NPV negative predictive value
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factors to select patients for screening also the predictive
values are comparable. In a multi-center prospective study
of Senft et al. [6], 92 patients with the same high-risk
factors as used in this study (33% developed distant
metastases), underwent screening for distant metastases by
chest CT and whole body FDG-PET. Using a reference
standard of 12-month follow-up, the sensitivity, specificity,
positive predictive value, and negative predictive value of
were for chest CT 37, 95, 79, and 75%, for FDG-PET 53,
93, 80, and 80% and for the combination (visual correla-
tion) of chest and FDG-PET 63, 95, 86, and 84%, respec-
tively. These figures improved when patients who
developed distant metastases and locoregional recurrences
simultaneously during follow-up were excluded, because
no distinction can be made between growth of subclinical
metastases already present at the time of screening and
reseeding of a locoregional recurrence after initial screen-
ing: for chest CT 50, 95, 79, and 83%, for FDG-PET 68,
93, 79, and 89%, and for the combination (visual correla-
tion) of chest and FDG-PET 82, 95, 86, and 93%, respec-
tively [6].
Xu et al. [9] performed a meta-analysis on the accuracy
of whole body FDG-PET/CT in staging of head and neck
cancer. For the staging of head and neck cancer other than
nasopharyngeal cancer, a pooled sensitivity and specificity
of 88.8% [95% confidence interval (CI) 80.3–94.5] and
93.3% [95% CI 91.0–94.5%], respectively, were found for
PET/CT. The pooled studies used different reference
standards. The diagnostic value of PET/CT was not sig-
nificantly better than PET only [9].
In 27 untreated HNSCC patients with mainly advanced
HNSCC and 19% distant metastases, Gourin et al. [14]
reported for the detection of distant metastases by FDG-
PET/CT a sensitivity of 100%. However, when 12-month
follow-up was used as reference standard, the sensitivity
decreased to 60% and specificity, positive predictive value,
and negative predictive value were 95, 75, and 91%,
respectively [14]. In the later study of the same group [15]
in 64 patients with suspected recurrent HNSCC following
definitive treatment, the incidence of distant metastases
was 23%. Using a reference standard of 12-month follow-
up, the sensitivity, specificity, positive predictive value,
and negative predictive value for the detection of distant
metastases by PET/CT were 86, 84, 60, and 95%, respec-
tively [15]. The higher sensitivity and lower specificity in
this second group are suggestive for a more sensitive
reading.
Krabbe et al. [16] reported on screening for distant
metastases by FDG-PET in 149 HNSCC patients. In thir-
teen (8.7%) of these patients, distant metastases were
detected during screening or follow-up of at least
6 months. Using this follow-up as the reference standard, a
sensitivity of 85% and a specificity of 93% for FDG-PET
were found. In the subgroup of 82 patients who underwent
both FDG-PET and chest ceCT, these figures were 82 and
92% for FDG-PET, compared to 55 and 63%, respectively,
for chest ceCT [16].
Ng et al. [8] compared the detection of distant malig-
nancies (distant metastases and second primary tumors) by
FDG-PET and extended-field ceCT of the chest in 160
newly diagnosed oropharyngeal and hypopharyngeal
squamous cell carcinoma patients with negative results
from chest radiography, liver ultrasound, and bone scan-
ning, with a follow-up of 12 months. Twenty-six (16.3%)
of these patients developed distant malignancies. The
percentages of additionally detected distant malignancies
by FDG-PET and ceCT were 12.5 and 8.1%, respectively.
The sensitivity of FDG-PET was significantly higher (76.9
vs. 50.0%), while its specificity was slightly lower (94.0 vs.
97.8%) than ceCT. Visual correlation of FDG-PET and CT
improved the sensitivity and specificity to 80.8 and 98.5%,
respectively, leading to alteration of treatment in 13.1% of
patients [8].
Haerle et al. [12] reported on 299 patients with advanced
stage HNSCC who underwent screening for distant
metastases using FDG-PET/non-ceCT. PET/CT detected
distant metastases in 29 (10%) patients, while in 30 (11%)
patients, distant metastases were diagnosed during a med-
ian follow-up of 30 months (range 1–72 months). A sen-
sitivity of 97% and a specificity of 95% were reported
using a reference standard of 6 months. When long-term
follow-up was used as reference standard, the sensitivity
decreased to 48% [12].
Recently, Suenaga et al. [18] reported on 170 patients
previously treated for HNSCC with suspected recurrence
who underwent PET/CT, consisting of non-ceCT and
ceCT, to investigate. In 8.8% of the patients, distant
metastases were detected during screening or follow-up of
at least 12 months. The sensitivity and specificity for chest
ceCT were 33 and 99%, for PET/CT with non-ceCT 53 and
99%, and for PET/CT with ceCT 60 and 99%, respectively.
They concluded that the added value of ceCT at FDG-PET/
CT is minimal, statistically not significant and likely not
clinically relevant [18].
From the reported studies, it can be concluded that the
specificity and negative predictive value for chest CT and
whole body PET(/CT) are generally high. In the reported
studies, when the follow-up (as reference standard)
increased from 6, to 12, and to 24 months, the sensitivity
for chest CT decreased from 100%, to 37–73%, and to
33%, respectively, and for the combination of PET and CT
(visually correlated and integrated) from 92–97, to
63–82%, and to 48% (30 months). In this study, the
accuracy was determined using the different reference
standards in the same cohort of patients. The results of
these analyses confirm the results found in the reported
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studies. This is illustrated by the sensitivity of the combi-
nation of chest ceCT and 18-FDG-PET/CT: 83% after
6-month follow-up, 60% after 12-month follow-up and
38% after a median follow-up of 30.2 months.
When only patients with locoregional control during
surveillance were analyzed the sensitivity increased up to
23%. In this study, sensitive reading improved the sensi-
tivity up to 34% for CT and up to 17% for PET/CT, while
the specificity decreased but remained high.
Now, the question arises if for pretreatment screening
for distant metastases these diagnostic techniques are suf-
ficient enough? When it is the physicians’ opinion that an
interval between HNSCC diagnosis and manifest distant
metastases of at least 12 months justifies extensive
locoregional treatment [20], one could argue that the sen-
sitivity of 60–82% for the combination of PET and chest
CT may be acceptable. Then, in the future studies,
12-month follow-up as reference standard will be
sufficient.
Nevertheless, this critical appraisal on the reference
standards used in the reported studies shows room for
improvement for the detection of distant metastases. Due to
the introduction of multi-channel receiver MRI, whole
body MRI has become clinically feasible, with substan-
tially reduced examination times [21]. Chan et al. [22]
reported on 103 untreated oro- and hypopharyngeal carci-
noma patients who underwent screening using FDG-PET–
CT and WB-MRI. Distant metastases (n = 8) or second
primary tumors (n = 10) were detected in 18 (17.5%)
patients. Using a follow-up of at least 12 months as a
reference standard, the sensitivity, specificity, positive, and
negative predictive values of WB-MRI were 67, 96, 80,
and 93%, respectively. The figures for PET–CT were 83,
95, 79, and 94%, respectively. For combined reading, these
figures were 78, 98, 88, and 95%, respectively. The diag-
nostic capability of PET–CT seems higher, but this dif-
ference was statistically non-significant. Technical
improvements like diffusion-weighted whole body imaging
with background-body-signal-suppression (DWIBS) and
experience in whole body MRI may increase the accuracy
of this technique. With the rising concern of radiation dose
in medical imaging, WB-MRI may be considered as a
potential replacement for PET–CT for the whole body
screening of patients. However, at the moment, none of
these new methods have proved to be better for this topic.
With the introduction of PET–MRI fusion studies, com-
bined readings may improve the detection of distant
metastases in the near future.
In conclusion, for pretreatment screening on distant
metastases in HNSCC patients with high-risk factors,
18FDG-PET/ceCT should be performed. The reported
accuracy, particularly sensitivity, of chest CT, 18FDG-
PET/non-ceCT, and 18FDG-PET/ceCT for the detection of
distant metastases is highly dependent on the reference
standard used. A reference standard of 12 months may be
sufficient, although still only half of the subclinical distant
metastases missed during initial screening will become
manifest within this time period. There is room for better
diagnostic screenings techniques to refrain more patients
from unnecessary extensive locoregional treatment for
occult metastatic HNSCC.
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